0QLR - Ticker AI Digest

Novartis AG 📰 1
TradingFloor AI GRID GO VIP Login

Digested News

All RNS Today (0QLR) 1
0QLR 05:16
Novartis AG
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
AI 0
No items for this category on selected date.
Acquisitions 1
0QLR 05:03
Novartis AG
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
Agreement 0
No items for this category on selected date.
Approvals 1
0QLR 05:16
Novartis AG
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
0QLR 05:16
Novartis AG
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 1
0QLR 20:36
Novartis AG
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
0QLR 14:01
Novartis AG
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All RNS (Last 30 Days) 17
0QLR 05:16
Novartis AG
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis
0QLR 05:16
Novartis AG
Alcon to develop SMART Suite digital health platform for cataract surgery
0QLR 22:31
Novartis AG
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed
0QLR 07:16
Novartis AG
Novartis COMBI-AD study of Tafinlar® + Mekinist® continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
0QLR 14:31
Novartis AG
Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone
0QLR 14:01
Novartis AG
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
0QLR 05:16
Novartis AG
Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden
0QLR 05:03
Novartis AG
Novartis announces planned acquisition of Endocyte to expand expertise in radiopharmaceuticals and build on commitment to transformational therapeutic platforms
0QLR 05:01
Novartis AG
Novartis delivered strong growth and innovation during the third quarter, including progressing advanced therapy platforms to drive future growth
0QLR 05:16
Novartis AG
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
0QLR 20:36
Novartis AG
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
0QLR 20:31
Novartis AG
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis
0QLR 05:16
Novartis AG
Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden
0QLR 20:31
Novartis AG
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
0QLR 05:16
Novartis AG
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
0QLR 05:16
Novartis AG
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
0QLR 05:16
Novartis AG
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals

AI Crunch

Single-Ticker AI Crunch
0QLR signal theatre built from scored RNS, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Novartis AG. It compresses bullish and bearish RNS scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full 0QLR AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored RNS row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Upcoming earnings radar so catalysts sit next to the news flow.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for 0QLR on 2018-10-26.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
195431300000
Enterprise Value
-
Public Float
-
Broker Target
-
Shares Out
-
Long Interest
64
Short Interest
36
Exchange
LSE
Currency Code
GBP
ISIN
CH0012005267
Market
None
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-02-04
Net Debt
-
Cash
-
EPS
-
Net Income
-
Revenue
-
Enterprise Value
-
Trailing PE
-
Forward PE
-
Price Sales TTM
-
Price Book MRQ
-
EV Revenue
-
EV EBITDA
-

Capital Radar

Capital Regime
Loading
Building signal blend...
Smart Money Tilt
Loading
Public vs institutions
Target Conviction
Loading
Broker coverage pulse
Insider Pressure
Loading
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
-
Institutions As Of
-
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
0
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

0QLR Price History Last 30 Days
Chart Intelligence Suite
Turn every chart into a live signal desk built to surface conviction in seconds.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and RNS beacons pin market-moving disclosures directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD RNS Beacons Live Price Structure
TradingFloor AI GRID Member Login
Indicators
Technicals
RSI Gauge
Price Change
AI Forecast
Loading